Lipella Pharmaceuticals Inc. (LIPO)
OTCMKTS
· Delayed Price · Currency is USD
0.6397
0.00 (0.00%)
Aug 15, 2025, 2:41 PM EDT
Lipella Pharmaceuticals Revenue
Lipella Pharmaceuticals had revenue of $86.73K in the quarter ending June 30, 2025, a decrease of -36.43%. This brings the company's revenue in the last twelve months to $470.16K, down -7.30% year-over-year. In the year 2024, Lipella Pharmaceuticals had annual revenue of $536.36K with 19.29% growth.
Revenue (ttm)
470.16K
Revenue Growth
-7.30%
P/S Ratio
5.99
Revenue / Employee
78.36K
Employees
7
Market Cap
2.81M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 221.55M |
Elite Pharmaceuticals | 84.04M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
BioStem Technologies | 332.45M |
Lipella Pharmaceuticals News
- 7 weeks ago - Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting - GlobeNewsWire
- 2 months ago - Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market - GlobeNewsWire
- 2 months ago - Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology - GlobeNewsWire
- 4 months ago - Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine” - GlobeNewsWire
- 5 months ago - Spartan Capital Securities, LLC Announces Key February Transactions - GlobeNewsWire
- 5 months ago - Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement - GlobeNewsWire
- 6 months ago - Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes - Benzinga
- 6 months ago - Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus - GlobeNewsWire